Latest Pharma Insights
Biotechs Cash In On Priority Review Vouchers As Record Sales Signal Rising Demand
Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their highest since 2016.
Scrip - October 23, 2026
Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their highest since 2016.
Scrip - October 23, 2026
Investors Bet That Star Can Repeat Past Successes With $200m Financing
Star Therapeutics, which sold subsidiary Vega to Incyte for $1.26bn up front this year, raised $200m in private financing to take its next round of novel biologics into the clinic.
Scrip - October 23, 2026
Star Therapeutics, which sold subsidiary Vega to Incyte for $1.26bn up front this year, raised $200m in private financing to take its next round of novel biologics into the clinic.
Scrip - October 23, 2026
France’s Alma Urges Off-Patent Exemption From Latest Legislative Burdens
French off-patent industry association Alma has urged revisions to the country’s latest social security financing bill to avoid penalizing generics and biosimilars.
Generics Bulletin - October 23, 2026
French off-patent industry association Alma has urged revisions to the country’s latest social security financing bill to avoid penalizing generics and biosimilars.
Generics Bulletin - October 23, 2026
Formycon Goes After Its First Niche-Buster Biosimilar With A Latin American Partner
Formycon has partnered with Uruguay-based Biocelys to develop an undisclosed “niche-buster” biosimilar, FYB286, targeting a rare disease. The deal is financed upfront by Santo Biosimilar, an entity controlled by Athos KG, which also controls Biocelys and is Formycon’s largest anchor shareholder.
Generics Bulletin - October 23, 2026
Formycon has partnered with Uruguay-based Biocelys to develop an undisclosed “niche-buster” biosimilar, FYB286, targeting a rare disease. The deal is financed upfront by Santo Biosimilar, an entity controlled by Athos KG, which also controls Biocelys and is Formycon’s largest anchor shareholder.
Generics Bulletin - October 23, 2026
The Biological Case for Adopting New Approach Methodologies in Oncology
The FDA’s oncology draft guidance supports using human-relevant NAMs to replace or augment animal toxicology studies, with biologics and ADCs best positioned because their targeted behavior makes safety predictable.
In Vivo - October 23, 2026
The FDA’s oncology draft guidance supports using human-relevant NAMs to replace or augment animal toxicology studies, with biologics and ADCs best positioned because their targeted behavior makes safety predictable.
In Vivo - October 23, 2026
Gilead Licenses Rival To J&J’s Icotyde In IBD Race Catch-Up
Deal Snapshot: Gilead is paying Pepstar/Peptidstar $1.3bn upfront for an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life in a bid to catch up with J&J’s Icotyde in inflammatory bowel disease.
Scrip - October 23, 2026
Deal Snapshot: Gilead is paying Pepstar/Peptidstar $1.3bn upfront for an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life in a bid to catch up with J&J’s Icotyde in inflammatory bowel disease.
Scrip - October 23, 2026
Roche Diagnostics Says China Drag Is Easing As It Eyes Return To Mid-to-High Single-Digit Growth
Roche’s diagnostics division grew 4% in the first nine months of 2026, but the more telling number is what happened in China: a 13% year-to-date decline that is narrowing, with Q3 alone coming in at minus 9% as pricing reform pressure eases.
Medtech Insight - October 23, 2026
Roche’s diagnostics division grew 4% in the first nine months of 2026, but the more telling number is what happened in China: a 13% year-to-date decline that is narrowing, with Q3 alone coming in at minus 9% as pricing reform pressure eases.
Medtech Insight - October 23, 2026
Edwards Lands FDA Nod For PASCAL In Tricuspid Repair, Setting Up Direct Challenge To Abbott’s TriCli
FDA approved Edwards’ PASCAL Precision for tricuspid edge-to-edge repair, giving US clinicians a second clip-based option after Abbott’s TriClip, with Medicare coverage already in place but pivotal CLASP IITR data still to come.
Medtech Insight - October 23, 2026
FDA approved Edwards’ PASCAL Precision for tricuspid edge-to-edge repair, giving US clinicians a second clip-based option after Abbott’s TriClip, with Medicare coverage already in place but pivotal CLASP IITR data still to come.
Medtech Insight - October 23, 2026
Biotechs Cash In On Priority Review Vouchers As Record Sales Signal Rising Demand
Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their highest since 2016.
Scrip - October 23, 2026
Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their highest since 2016.
Scrip - October 23, 2026
Investors Bet That Star Can Repeat Past Successes With $200m Financing
Star Therapeutics, which sold subsidiary Vega to Incyte for $1.26bn up front this year, raised $200m in private financing to take its next round of novel biologics into the clinic.
Scrip - October 23, 2026
Star Therapeutics, which sold subsidiary Vega to Incyte for $1.26bn up front this year, raised $200m in private financing to take its next round of novel biologics into the clinic.
Scrip - October 23, 2026
Gilead Licenses Rival To J&J’s Icotyde In IBD Race Catch-Up
Deal Snapshot: Gilead is paying Pepstar/Peptidstar $1.3bn upfront for an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life in a bid to catch up with J&J’s Icotyde in inflammatory bowel disease.
Scrip - October 23, 2026
Deal Snapshot: Gilead is paying Pepstar/Peptidstar $1.3bn upfront for an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life in a bid to catch up with J&J’s Icotyde in inflammatory bowel disease.
Scrip - October 23, 2026
Roche Diagnostics Says China Drag Is Easing As It Eyes Return To Mid-to-High Single-Digit Growth
Roche’s diagnostics division grew 4% in the first nine months of 2026, but the more telling number is what happened in China: a 13% year-to-date decline that is narrowing, with Q3 alone coming in at minus 9% as pricing reform pressure eases.
Medtech Insight - October 23, 2026
Roche’s diagnostics division grew 4% in the first nine months of 2026, but the more telling number is what happened in China: a 13% year-to-date decline that is narrowing, with Q3 alone coming in at minus 9% as pricing reform pressure eases.
Medtech Insight - October 23, 2026
Edwards Lands FDA Nod For PASCAL In Tricuspid Repair, Setting Up Direct Challenge To Abbott’s TriCli
FDA approved Edwards’ PASCAL Precision for tricuspid edge-to-edge repair, giving US clinicians a second clip-based option after Abbott’s TriClip, with Medicare coverage already in place but pivotal CLASP IITR data still to come.
Medtech Insight - October 23, 2026
FDA approved Edwards’ PASCAL Precision for tricuspid edge-to-edge repair, giving US clinicians a second clip-based option after Abbott’s TriClip, with Medicare coverage already in place but pivotal CLASP IITR data still to come.
Medtech Insight - October 23, 2026
Abbott To Spin Off Nutrition, Leaving A Diagnostics And Devices Core As Formula Suits Linger
Abbott is spinning off its $8.5bn nutrition business in 2027 with roughly 1,700 infant-formula lawsuits still pending — and CEO Robert Ford has yet to say whether that legal exposure stays with Abbott or goes with the new company.
HBW Insight - October 22, 2026
Abbott is spinning off its $8.5bn nutrition business in 2027 with roughly 1,700 infant-formula lawsuits still pending — and CEO Robert Ford has yet to say whether that legal exposure stays with Abbott or goes with the new company.
HBW Insight - October 22, 2026
Second Swing For Lumineux ’30 Minutes To Whiter Teeth’ Claim’ Showed Results Too Good To Be True
NAD found “fatal flaws” in three studies Oral Essentials submitted in second review of “30 minutes to whiter teeth” claim it had considered in 2023 review which also found the firm didn’t support superiority claims challenged by Crest 3D White Whitestrips marketer P&G.
HBW Insight - October 22, 2026
NAD found “fatal flaws” in three studies Oral Essentials submitted in second review of “30 minutes to whiter teeth” claim it had considered in 2023 review which also found the firm didn’t support superiority claims challenged by Crest 3D White Whitestrips marketer P&G.
HBW Insight - October 22, 2026
EU Parliament Reportedly Clears Omnibus VI; US FDA Finalizes Cosmetic Recall Guidance
The European Parliament has approved the Omnibus VI package, says the EFfCI, as the US FDA has finalized its mandatory cosmetic recall guidance under MoCRA.
HBW Insight - October 22, 2026
The European Parliament has approved the Omnibus VI package, says the EFfCI, as the US FDA has finalized its mandatory cosmetic recall guidance under MoCRA.
HBW Insight - October 22, 2026
EU Urged To Follow US Lead On Rx-To-OTC Switch Exclusivity
AESGP wants EU data protection for switch evidence extended to three years and has presented eight recommendations to simplify switch pathways. The call comes as naloxone spray Nyxoid is poised to become only the seventh active substance switched through the EU's centralised route.
HBW Insight - October 22, 2026
AESGP wants EU data protection for switch evidence extended to three years and has presented eight recommendations to simplify switch pathways. The call comes as naloxone spray Nyxoid is poised to become only the seventh active substance switched through the EU's centralised route.
HBW Insight - October 22, 2026
Page Error Or Postponement? Commission Says No 2026 Consultation Planned On EU Supplement Limits
Exclusive: The EC says no consultation on EU supplement vitamin and mineral limits is planned for 2026, calling its Q3 listing an error. FoodChain ID’s Jérôme Le Bloch says the delay may give the EC time to finalize a more refined proposal, but should not shorten stakeholders’ window to comment.
HBW Insight - October 22, 2026
Exclusive: The EC says no consultation on EU supplement vitamin and mineral limits is planned for 2026, calling its Q3 listing an error. FoodChain ID’s Jérôme Le Bloch says the delay may give the EC time to finalize a more refined proposal, but should not shorten stakeholders’ window to comment.
HBW Insight - October 22, 2026
GLP-1s Key Factor In Changes To Nutritional Needs Supplement Firms Should Meet – NIH Official
NIH nutrition research and dietary supplement chief Andrew Bremer says providing nutritionals for consumers receiving drug treatments, such as GLP-1 patients, or who have conditions causing low nutrition levels is “extraordinary opportunity” for supplement industry.
HBW Insight - October 22, 2026
NIH nutrition research and dietary supplement chief Andrew Bremer says providing nutritionals for consumers receiving drug treatments, such as GLP-1 patients, or who have conditions causing low nutrition levels is “extraordinary opportunity” for supplement industry.
HBW Insight - October 22, 2026
AI Chatbots Are Fielding Beauty Shoppers’ Questions. Brands May Be Responsible For Answers
In an Oct. 20 interview, NAD attorney Laura Protzmann said a beauty brand’s exposure for what a chatbot says turns on how much control it has, and warned that the line may blur as brands work to shape the information third-party chatbots relay.
HBW Insight - October 22, 2026
In an Oct. 20 interview, NAD attorney Laura Protzmann said a beauty brand’s exposure for what a chatbot says turns on how much control it has, and warned that the line may blur as brands work to shape the information third-party chatbots relay.
HBW Insight - October 22, 2026
France’s Alma Urges Off-Patent Exemption From Latest Legislative Burdens
French off-patent industry association Alma has urged revisions to the country’s latest social security financing bill to avoid penalizing generics and biosimilars.
Generics Bulletin - October 23, 2026
French off-patent industry association Alma has urged revisions to the country’s latest social security financing bill to avoid penalizing generics and biosimilars.
Generics Bulletin - October 23, 2026
Formycon Goes After Its First Niche-Buster Biosimilar With A Latin American Partner
Formycon has partnered with Uruguay-based Biocelys to develop an undisclosed “niche-buster” biosimilar, FYB286, targeting a rare disease. The deal is financed upfront by Santo Biosimilar, an entity controlled by Athos KG, which also controls Biocelys and is Formycon’s largest anchor shareholder.
Generics Bulletin - October 23, 2026
Formycon has partnered with Uruguay-based Biocelys to develop an undisclosed “niche-buster” biosimilar, FYB286, targeting a rare disease. The deal is financed upfront by Santo Biosimilar, an entity controlled by Athos KG, which also controls Biocelys and is Formycon’s largest anchor shareholder.
Generics Bulletin - October 23, 2026
The Biological Case for Adopting New Approach Methodologies in Oncology
The FDA’s oncology draft guidance supports using human-relevant NAMs to replace or augment animal toxicology studies, with biologics and ADCs best positioned because their targeted behavior makes safety predictable.
In Vivo - October 23, 2026
The FDA’s oncology draft guidance supports using human-relevant NAMs to replace or augment animal toxicology studies, with biologics and ADCs best positioned because their targeted behavior makes safety predictable.
In Vivo - October 23, 2026